- Home
- VYGR vs ACRE Comparison
VYGR vs ACRE Comparison
Compare VYGR & ACRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYGR
- ACRE
- Stock Information
- Founded
- VYGR 2013
- ACRE 2011
- Country
- VYGR United States
- ACRE United States
- Employees
- VYGR N/A
- ACRE N/A
- Industry
- VYGR Biotechnology: Pharmaceutical Preparations
- ACRE Real Estate Investment Trusts
- Sector
- VYGR Health Care
- ACRE Real Estate
- Exchange
- VYGR Nasdaq
- ACRE Nasdaq
- Market Cap
- VYGR 232.4M
- ACRE 254.1M
- IPO Year
- VYGR 2015
- ACRE 2012
- Fundamental
- Price
- VYGR $3.99
- ACRE $5.28
- Analyst Decision
- VYGR Strong Buy
- ACRE Hold
- Analyst Count
- VYGR 7
- ACRE 5
- Target Price
- VYGR $16.17
- ACRE $5.08
- AVG Volume (30 Days)
- VYGR 468.8K
- ACRE 483.4K
- Earning Date
- VYGR 11-10-2025
- ACRE 11-07-2025
- Dividend Yield
- VYGR N/A
- ACRE 11.45%
- EPS Growth
- VYGR N/A
- ACRE N/A
- EPS
- VYGR N/A
- ACRE N/A
- Revenue
- VYGR $31,316,000.00
- ACRE $87,777,000.00
- Revenue This Year
- VYGR N/A
- ACRE N/A
- Revenue Next Year
- VYGR $107.10
- ACRE N/A
- P/E Ratio
- VYGR N/A
- ACRE N/A
- Revenue Growth
- VYGR N/A
- ACRE 122.65
- 52 Week Low
- VYGR $2.65
- ACRE $3.35
- 52 Week High
- VYGR $7.44
- ACRE $7.49
- Technical
- Relative Strength Index (RSI)
- VYGR 41.99
- ACRE 65.59
- Support Level
- VYGR $3.81
- ACRE $4.77
- Resistance Level
- VYGR $4.30
- ACRE $4.94
- Average True Range (ATR)
- VYGR 0.26
- ACRE 0.19
- MACD
- VYGR -0.01
- ACRE 0.04
- Stochastic Oscillator
- VYGR 38.14
- ACRE 88.89
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
About ACRE Ares Commercial Real Estate Corporation
Ares Commercial Real Estate Corp is a specialty finance company and a Real Estate Investment Trust providing commercial real estate loans and related investments. It operates in one segment namely originating and managing a diversified portfolio of CRE debt-related investments. The group recognizes its revenues through the interest income it receives from loans.